Sandu Pharmaceuticals reported a net profit of ₹22.82 lakh for the quarter ended June 30, 2026 (Q1FY27), marking a 2.2% year-on-year increase from ₹22.33 lakh in Q1FY26. Revenue from operations declined 1.9% to ₹1,638.88 lakh, while total expenses were contained at ₹1,604.57 lakh. Earnings per share (basic) increased to ₹0.37 from ₹0.23.

For the full financial year ended March 31, 2026 (FY26), the company recorded a 23.2% increase in net profit to ₹176.62 lakh compared to ₹154.89 lakh in FY25. Revenue from operations rose 4.1% to ₹6,993.45 lakh from ₹6,719.24 lakh in the previous year. Total income stood at ₹7,037.89 lakh, while total expenses were ₹6,772.34 lakh. Profit before tax grew 23.2% to ₹265.56 lakh. Earnings per share (basic) improved to ₹1.83 from ₹1.60 in the prior year.

Financial Performance Highlights

The Board of Directors approved the unaudited standalone financial results on August 11, 2026. The company also announced that its 41st Annual General Meeting (AGM) will be held on September 11, 2026, via Video Conferencing. The Register of Members will remain closed from September 4, 2026, to September 11, 2026.

Auditor Appointment and Related Party Transactions

The Board recommended the appointment of M/s. Dave & Dave, Chartered Accountants, as Statutory Auditors for a first term of five consecutive years, commencing from the conclusion of the ensuing AGM until the AGM in 2031. This appointment is subject to shareholder approval. Additionally, the Board sought member approval for the continuation of Material Related Party Transactions with M/s. Sandu Brothers Private Limited.

What the Numbers Show

Despite a marginal decline in top-line revenue in Q1FY27, Sandu Pharmaceuticals improved its bottom line through efficient cost control. For FY26, the company achieved a healthy expansion in both revenue and profitability, with net profit growth outpacing revenue growth. The significant improvement in earnings per share underscores the impact of consistent profitability on shareholder value.

Sandu Pharmaceuticals Limited has redesignated Shri Balram Viswanathan as Chairman and Managing Director for a term of three years effective July 11, 2026. The board also appointed Dr. Neeti Madan Kapre as an Additional Non-Executive Independent Director for a five-year term. These decisions follow the demise of former Managing Director Shri Umesh B. Sandu on June 19, 2026.

Board Appointments and Redesignations

The board approved the redesignation of Shri Balram Viswanathan from Chairman and Non-Executive Independent Director to Chairman and Managing Director. His appointment is subject to shareholder approval at the ensuing general meeting. Additionally, Dr. Neeti Madan Kapre was appointed as an Additional Non-Executive Independent Director effective July 11, 2026, until July 10, 2031, subject to shareholder approval.

Committee Reconstitution and Policy Updates

Pursuant to the leadership changes, the board reconstituted the Audit Committee, Nomination and Remuneration Committee, and Stakeholders' Relationship Committee. The board also revised the Vigil Mechanism Policy to replace the name of the late Shri Umesh B. Sandu with Shri Balram Viswanathan as the Chairman and Managing Director.

Key Appointments Summary

The disclosures were made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.